Terapi Potensial Terkini Corona Virus Disease 2019 (COVID19)
DOI:
https://doi.org/10.55175/cdk.v47i4.371Keywords:
COVID-19, SARS-CoV-2, terapi potensialAbstract
SARS-CoV-2 adalah virus yang menginfeksi saluran pernapasan dan merupakan penyebab penyakit corona virus disease 2019 (COVID19). Meskipun belum ada tatalaksana yang spesifik untuk COVID-19, saat ini sudah banyak obat-obatan yang berpotensi untuk dapat menjadi pilihan terapi yang menjanjikan. Artikel ini akan merangkum beberapa obat-obatan, mulai dari obat-obatan yang sudah umum digunakan di dunia kedokteran seperti Ivermectin, hingga obat-obatan dari tumbuhan herbal yang memiliki potensi untuk dapat menjadi tatalaksana COVID-19.
SARS-CoV-2 is a virus that infects the respiratory tract and causing coronavirus disease 2019 (COVID19). Although there is no specific treatment for COVID-19, there are many drugs that have potential to become promising therapeutic choices. This article will summarize some medicines, both drugs that are commonly used in the medical world such as Ivermectin, to medicines from herbal plants that have the potential to be a COVID-19 treatment.
Downloads
References
Lupia T, Scabini S, Mornese Pinna S, Di Perri G, De Rosa F, Corcione S. 2019 novel coronavirus (2019-nCoV) outbreak: A new challenge. J Glob Antimicrob Resist. 2020;21:22-7.
Gasmi A, Noor S, Tippairote T, Dadar M, Menzel A, Bjørklund G. Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic. Clin Immunol. 2020:108409. doi:10.1016/j.clim.2020.108409
EBSCO Information Services. More.ebsco.com [Internet]. 2020 [cited 2020 April 12]. Available from: https://more.ebsco.com/EBSCO-COVID-19-ResourceCenter.html.
González Canga A, Sahagún Prieto AM, DiezLiébana MJ, FernándezMartínez N, Sierra Vega M, GarcíaVieitez JJ. The pharmacokinetics and interactions of ivermectin in humans--a mini-review. AAPS J. 2008;10(1):42–6.
Caly L, Druce J, Catton M, Jans D, Wagstaff K. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020:104787. doi:10.1016/j.antiviral.2020.104787
Buonfrate D, Salas-Coronas J, Muñoz J, Maruri BT, Rodari P, Castelli F, et al. Multiple-dose versus single-dose ivermectin for Strongyloidesstercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial. Lancet Infect Dis. 2019;19(11):1181-90.
Monteil V, Kwon H, Prado P, Hagelkruys A, Wimmer R, Stahl M. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell Press. 2020. DOI: 10.1016/j.cell.2020.04.004
Rothan H, Byrareddy S. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433.
Read S, Obeid S, Ahlenstiel C, Ahlenstiel G. The Role of Zinc in Antiviral Immunity. Advances in Nutrition. 2019;10(4):696-710.
Suara R, Crowe J. Effect of zinc salts on respiratory syncytial virus replication. Antimicrob Agents Chemother. 2004;48(3):783-90.
Kar M, Khan N, Panwar A, Bais SS, Basak S, Goel R, et al. Zinc chelation specifically inhibits early stages of dengue virus replication by activation of NF-κB and induction of antiviral response in epithelial cells. Front Immunol. 2019;10. doi:10.3389/fimmu.2019.02347
Kaushik N, Anang S, Ganti K, Surjit M. Zinc: A potential antiviral against hepatitis E virus infection? DNA Cell Biol. 2018;37(7):593-9.
teVelthuis AJ, van den Worm SH, Sims AC, Baric RS, Snijder EJ, van Hemert MJ. Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoSPathog. 2010;6(11):1001176.
The University of Melbourne. World-first trial to test benefit of intravenous zinc in COVID-19 fight [Internet]. 2020 [cited 2020 April 12]. Available from: https://about.unimelb.edu.au/newsroom/news/2020/april/world-first-trial-to-test-benefit-of-intravenous-zinc-in-covid-19-fight.
David S, Cunningham R. Echinacea for the prevention and treatment of upper respiratory tract infections: A systematic review and meta-analysis. Complement Ther Med. 2019;44:18-26.
Hudson J, Vimalanathan S. Echinacea—A source of potent antivirals for respiratory virus infections. Pharmaceuticals (Basel). 2011;4(7):1019–31.
Jonsdottir HR, Signer J, Albrich WC, Strasser M, Zust R, Ryter S, et al. In vitro antiviral activity of Echinaforce®, an Echinacea purpurea preparation, against common cold coronavirus 229E and highly pathogenic MERS-CoV and SARS-CoV. 2020. doi:10.21203/rs.2.24724/v2
Jo S, Kim S, Shin D, Kim M. Inhibition of SARS-CoV 3CL protease by flavonoids. J Enzyme Inhib Med Chem. 2019;35(1):145-51.
Jo S, Kim H, Kim S, Shin D, Kim M. Characteristics of flavonoids as potent MERS-CoV 3C-like protease inhibitors. ChemBiol Drug Des. 2019;94(6):2023-30.
Ryu Y, Jeong H, Kim J et al. Biflavonoids from Torreyanucifera displaying SARS-CoV 3CLpro inhibition. Bioorg Med Chem. 2010;18(22):7940-7.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Cermin Dunia Kedokteran
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
